SIGLEC1 and lung carcinoma: In our study, AM of patients suffering from SSc-ILD, in comparison with AM from lung cancers, also had a significantly enhanced expression of the M2 polarization marker CD206 and a higher percentage of positive cells for CD169 and CD163.